Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharm...(icalantifungal steroid combination and N...),Health

Date:3/19/2008

ical antifungal steroid combination, and Novacort(R) (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription topical steroid and anesthetic. CollaGenex recently completed a Phase II clinical trial to evaluate COL-118, a topical compound based on the SansRosa(R) technology, for the treatment of redness associated with rosacea and other skin disorders. CollaGenex recently acquired the rights to develop and commercialize becocalcidiol, a patented Vitamin D analogue that is currently in Phase II clinical trials for the topical treatment of mild to moderate psoriasis.

For more information on CollaGenex please visit CollaGenex's Web site at http://www.collagenex.com, which does not form part of this press release.

Important Information About the Tender Offer

Galderma Laboratories, Inc. and its wholly owned subsidiary, Galderma Acquisition Inc., have filed a Tender Offer Statement on Schedule TO containing an offer to purchase, forms of letters of transmittal and other documents relating to the tender offer, and CollaGenex Pharmaceuticals, Inc. has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. These documents contain important information about the tender offer that should be read carefully before any decision is made with respect to the tender offer.

Shareholders of CollaGenex can obtain a free copy of these documents and other documents filed by CollaGenex or Galderma Laboratories, Inc. with the U.S. Securities and Exchange Commission at their website, http://www.sec.gov, or from the Information Agent, Innisfree M&A Incorporated, through the numbers listed at the end of this press release.

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects may constitute forwar
'/>"/>

SOURCE Galderma Pharma S.A. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
2. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
3. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
4. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
5. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
6. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
7. PRA International Announces New Office Opening in Mumbai
8. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
9. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
10. Forest Laboratories Announces Resignation of Ivan Gergel, MD
11. National Parkinson Foundation Announces Its New President and CEO